213 related articles for article (PubMed ID: 34740949)
21.
Ouvrard E; Mestier L; Boursier C; Lachachi B; Sahakian N; Chevalier E; Mikail N; Carullo J; Bando-Delaunay A; Walter T; Malouf GG; Addeo P; Poncet G; Sebag F; Lebtahi R; Goichot B; Taïeb D; Imperiale A
J Nucl Med; 2022 Dec; 63(12):1865-1870. PubMed ID: 35589408
[TBL] [Abstract][Full Text] [Related]
22. Value of
Imperiale A; Boursier C; Sahakian N; Ouvrard E; Chevalier E; Sebag F; Addeo P; Taïeb D
J Nucl Med; 2022 Mar; 63(3):384-388. PubMed ID: 34272321
[TBL] [Abstract][Full Text] [Related]
23. Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68Ga-DOTATATE positron emission tomography/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors.
Filizoglu N; Ozguven S; Akin Telli T; Ones T; Dede F; Turoglu HT; Erdil TY
Nucl Med Commun; 2024 May; ():. PubMed ID: 38745508
[TBL] [Abstract][Full Text] [Related]
24.
Liberini V; Rampado O; Gallio E; De Santi B; Ceci F; Dionisi B; Thuillier P; Ciuffreda L; Piovesan A; Fioroni F; Versari A; Molinari F; Deandreis D
Front Med (Lausanne); 2020; 7():601853. PubMed ID: 33575262
[No Abstract] [Full Text] [Related]
25. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
[TBL] [Abstract][Full Text] [Related]
26.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
27. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
28. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors.
Thuillier P; Bourhis D; Metges JP; Le Pennec R; Amrane K; Schick U; Blanc-Beguin F; Hennebicq S; Salaun PY; Kerlan V; Karakatsanis N; Abgral R
Sci Rep; 2021 Mar; 11(1):4727. PubMed ID: 33649421
[TBL] [Abstract][Full Text] [Related]
31. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
32. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
33. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
34. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
Al-Ibraheem A; Bundschuh RA; Notni J; Buck A; Winter A; Wester HJ; Schwaiger M; Scheidhauer K
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2005-13. PubMed ID: 21792572
[TBL] [Abstract][Full Text] [Related]
35. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
36. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
37. Impact of Tumor Burden on Quantitative [
Werner RA; Hänscheid H; Leal JP; Javadi MS; Higuchi T; Lodge MA; Buck AK; Pomper MG; Lapa C; Rowe SP
Mol Imaging Biol; 2019 Aug; 21(4):790-798. PubMed ID: 30406512
[TBL] [Abstract][Full Text] [Related]
38. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
Chan H; Moseley C; Zhang L; Bergsland EK; Pampaloni MH; Van Loon K; Hope TA
Pancreas; 2019 Aug; 48(7):948-952. PubMed ID: 31268975
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]